Clarity Pharmaceuticals Ltd

CU6.ASX

Health Care

Clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.

Market Data

Price

$2.470

+0.0%

Market Cap

$906.3M

P/E Ratio

-100000.0x

EPS

$-0.279

Div. Yield

0.00%

52-Week Change

-0.4%

Recent Announcements

10 Apr 2026 Sph Neutral

Ceasing to be a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.

9 Apr 2026 Sph Neutral

Becoming a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.0305%).

26 Mar 2026 Sph Neutral

Becoming a substantial holder

Vanguard Group (The Vanguard Group, Inc. became a substantial holder (5.007%).

Get real-time alerts for CU6

Receive AI-powered earnings summaries and instant notifications when Clarity Pharmaceuticals Ltd releases results.